Pneumococcal vaccination and revaccination in the elderly population

Journal of Infectious Diseases

Volumn 201, Issue 5, 2010, Pages 659-661

  Nichol, Kristin L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ELDERLY CARE; HUMAN; INFECTION PREVENTION; NOTE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVACCINATION; VACCINATION;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 76449106760     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651376     Document Type: Note

References (13)

1. Centers for Disease Control and Prevention. 2009. Active Bacterial Core Surveillance Report, Emerging Infections Program Network. Streptococcus pneumonia, 2008. http://www.cdc.gov/abcs/survreports/spneu08.pdf. Accessed 13 January 2010.
2. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46(RR-8):1-24.
3. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16:308-318.
4. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 1:CD000422.
5. Torling J, Hedlund J, Konradsen H, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22:96-103.
6. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-1460.
7. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7: 597-606.
8. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007; 25:4029-4037.
9. Musher DM, Manoff SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516-524.
10. Manoff SB, Liss C, Caulfield MJ, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged ≥65 years. J Infect Dis 2010; 201: 525-533.
11. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
12. Schiller JS, Euler GL. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. National Center for Health Statistics and National Center for Immunization and Respiratory Diseases. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/data/hestat/ vaccine-coverage.htm. Accessed 13 January 2010.
13. Jackson LA, Baxter R, Naleway AL, et al. Patterns of pneumococcal vaccination and revaccination in the elderly and non-elderly adults: a Vaccine Safety Datalink Study. BMC Infect Dis 2009; 9:37.